ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors.
about
Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family membersDominance of ErbB-1 heterodimers in lung epithelial cells overexpressing ErbB-2. Both ErbB-1 and ErbB-2 contribute significantly to tumorigenicityDesign, synthesis and characterization of peptidomimetic conjugate of BODIPY targeting HER2 protein extracellular domainSignal processing in the TGF-beta superfamily ligand-receptor networkNEDD9/Arf6-dependent endocytic trafficking of matrix metalloproteinase 14: a novel mechanism for blocking mesenchymal cell invasion and metastasis of breast cancer.Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 ProteinThe Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor FamilyTrastuzumab in the management of gastroesophageal cancer: patient selection and perspectivesHeterodimerization of the epidermal-growth-factor (EGF) receptor and ErbB2 and the affinity of EGF binding are regulated by different mechanismsHER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancerRegulation of epidermal growth factor receptor down-regulation by UBPY-mediated deubiquitination at endosomesCellular effects of HER3-specific affibody moleculesStepwise movements in vesicle transport of HER2 by motor proteins in living cellsEndocytic down-regulation of ErbB2 is stimulated by cleavage of its C-terminus.Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells.Regulation of receptor tyrosine kinase signaling by endocytic trafficking.Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases.Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.Regulation of ErbB2 receptor status by the proteasomal DUB POH1.Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells.Prostate cancer and bone: the elective affinities.Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy.Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapyCoclustering of ErbB1 and ErbB2 revealed by FRET-sensitized acceptor bleaching.MicroRNA and HER2-overexpressing cancer.A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer.Distribution of resting and ligand-bound ErbB1 and ErbB2 receptor tyrosine kinases in living cells using number and brightness analysisHER2-mediated effects on EGFR endosomal sorting: analysis of biophysical mechanismsDifferent epidermal growth factor (EGF) receptor ligands show distinct kinetics and biased or partial agonism for homodimer and heterodimer formation.A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells.Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.Analysis of growth factor signaling in genetically diverse breast cancer linesNexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants.Integrin alpha5/beta1 mediates fibronectin-dependent epithelial cell proliferation through epidermal growth factor receptor activationEndocytosis and intracellular trafficking of ErbBs.New developments in the treatment of metastatic gastric cancer: focus on trastuzumabMolecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.The Functional Crosstalk between HER2 Tyrosine Kinase and TGF-β Signaling in Breast Cancer Malignancy.New advances on prostate carcinogenesis and therapies: involvement of EGF-EGFR transduction system.
P2860
Q21195197-EDBFED57-6B9A-404A-B2A1-88C76A8B6CE6Q22010838-B656F528-30EF-43D1-97B0-90F401D1EBBCQ24293331-F547CFA1-809F-4E96-92E9-329CC91BE79FQ25257731-7EB8B5CC-9D8A-4749-82AE-716A342E1204Q27310099-AFA520D8-0F76-44DD-99E5-DA7576EECFD7Q27667382-AC0FA274-A91C-4898-B6E2-FBE524E22F7AQ28073335-63A5731F-FDFD-4162-9EC5-216FCBB1D9FEQ28077666-786ED438-B7FC-47CB-94DB-5DF042AB7044Q28364239-F2C04FF0-DC52-46E6-BA89-285FC1D60AD5Q28476604-FB3A4CB6-E379-43F7-B929-041F2BD6ED5CQ28511379-42147801-A328-4165-B00C-5C0078665A94Q28727774-2E2B81FB-A512-4FCB-B03E-BFFF2B6D336CQ30479459-3C681D76-6727-4198-9E1B-70C57C561D10Q30479942-C98402E7-47F7-478B-80A6-FD7BB926831DQ31150111-F3AEC48F-501B-40F9-B16D-7C695301B1F7Q32029952-74761C67-A4E8-4F47-AFB7-FBD622B6F56EQ32062433-7D26C952-E0B0-4C38-9DAF-68696098990EQ33265628-79EACA7E-71F6-4CF0-9A6C-2C458408EA92Q33444766-957F2D1C-CC48-4479-AB2F-668565596079Q33576337-5ABD1BEF-8ADD-4824-AD67-DF68CCDF98EAQ33757791-A48F78C1-E759-467C-BFD4-D3D5FEBD167BQ33801908-87B42FC7-FBD3-48C8-A903-2BD08A41C953Q33828409-BDD4A79B-41A8-418C-AF06-EFC84AA021C3Q33954390-3F4B4EA2-1A21-4ABD-8EDA-0A2324461209Q33994744-D12400FE-1E5D-4AC2-ACE3-FEFB7E1DDEF3Q34077853-D93CD601-E925-4B4E-972A-87C8D3F26EB2Q34151773-2958DC70-95D0-4818-8B02-81DC07882851Q34183239-A90CE29E-5F6A-45D5-8C9F-EC65E4BBE678Q34249179-BDB47DF3-E64D-40D6-8300-105D25B01C53Q34430965-1F026431-9BAD-49FA-A476-A4580E932A50Q34483533-5D6B0BC9-FF78-4F58-848B-F3586ACFC387Q34483541-41E7B259-4139-425C-B368-2B55DACA2910Q34522964-F95357E0-204D-4060-A187-D751A89DBFCAQ34657670-01BD0C0B-5705-4ADE-ABC2-2395A5FCC7F5Q34735845-3C5BDB7A-E3F8-470D-BABE-22D9E3373099Q34827744-6BBE002D-3F1D-4A5B-8F35-D527755701D3Q34883258-9285C8D0-5ECC-41BC-8A56-11C279EB25FFQ35001415-A88FA35D-61FA-48C4-BA34-F632F4F0183CQ35005626-C9FD38AE-F1B5-45AE-9225-18B324647301Q35149046-A2C7556A-85D7-4EDB-8FF8-EC074898798F
P2860
ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
ErbB-2 amplification inhibits ...... ermal growth factor receptors.
@en
type
label
ErbB-2 amplification inhibits ...... ermal growth factor receptors.
@en
prefLabel
ErbB-2 amplification inhibits ...... ermal growth factor receptors.
@en
P2860
P356
P1476
ErbB-2 amplification inhibits ...... dermal growth factor receptors
@en
P2093
L K Opresko
R Worthylake
P2860
P304
P356
10.1074/JBC.274.13.8865
P407
P50
P577
1999-03-01T00:00:00Z